- Home
- MARPS vs CHRO Comparison
MARPS vs CHRO Comparison
Compare MARPS & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARPS
- CHRO
- Stock Information
- Founded
- MARPS 1956
- CHRO 2002
- Country
- MARPS United States
- CHRO United States
- Employees
- MARPS N/A
- CHRO N/A
- Industry
- MARPS Oil & Gas Production
- CHRO
- Sector
- MARPS Energy
- CHRO
- Exchange
- MARPS Nasdaq
- CHRO Nasdaq
- Market Cap
- MARPS 7.8M
- CHRO 8.4M
- IPO Year
- MARPS N/A
- CHRO 2024
- Fundamental
- Price
- MARPS $3.76
- CHRO $0.95
- Analyst Decision
- MARPS
- CHRO Strong Buy
- Analyst Count
- MARPS 0
- CHRO 1
- Target Price
- MARPS N/A
- CHRO N/A
- AVG Volume (30 Days)
- MARPS 10.6K
- CHRO 2.1M
- Earning Date
- MARPS 01-01-0001
- CHRO 05-13-2025
- Dividend Yield
- MARPS 8.74%
- CHRO N/A
- EPS Growth
- MARPS N/A
- CHRO N/A
- EPS
- MARPS 0.36
- CHRO N/A
- Revenue
- MARPS $1,036,019.00
- CHRO N/A
- Revenue This Year
- MARPS N/A
- CHRO N/A
- Revenue Next Year
- MARPS N/A
- CHRO N/A
- P/E Ratio
- MARPS $10.69
- CHRO N/A
- Revenue Growth
- MARPS N/A
- CHRO N/A
- 52 Week Low
- MARPS $3.75
- CHRO $0.45
- 52 Week High
- MARPS $5.20
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- MARPS 39.55
- CHRO 35.68
- Support Level
- MARPS $3.34
- CHRO $0.91
- Resistance Level
- MARPS $4.03
- CHRO $1.14
- Average True Range (ATR)
- MARPS 0.13
- CHRO 0.12
- MACD
- MARPS -0.01
- CHRO -0.01
- Stochastic Oscillator
- MARPS 60.87
- CHRO 17.04
About MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.